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Abstract
Background: Transcatheter aortic valve implantation (TAVI) is a treatment strategy for patients with severe aortic stenosis.
Although general anaesthesia (TAVI-GA) and sedation (TAVI-S) have previously been described for TAVI, the difference in safety
and efﬁcacy of both methods has not been studied in a randomized trial.
Methods: The INSERT trial was a single centre, controlled parallel-group trial with balanced randomization. Sixty-six patients
(68–94 yr) with acquired aortic stenosis undergoing transfemoral CoreValve™were assigned to TAVI-GA or TAVI-S. Comparable
operative risk was determined from risk-scores (EUROscore, STS-Score). Monitoring and anaesthetic drugs were standardized.
Near-Infrared-Spectroscopy was used to monitor cerebral-oxymetry blinded. Primary outcome was the perioperative
cumulative cerebral desaturation. As secondary outcomes, changes in neurocognitive function and respiratory and
haemodynamic adverse events were evaluated.
Results: Of 66 included patients, 62 (TAVI-GA: n=31, TAVI-S: n=31) were ﬁnally analysed. Baseline characteristics were
comparable. In 24 patients (39%) cerebral desaturation was observed. Cumulative cerebral desaturation was comparable (TAVI-
GA:(median [IQR]) (0[0/1308] s%) vs. TAVI-S:(0[0/276] s%); P=0.505) between the groups. Neurocognitive function did not change
within and between groups. Adverse eventsweremore frequently observed in TAVI-S patients (P<0.001). Bradypnoea (n=16, 52%)
and the need for airwaymanoeuvres (n=11, 36%) or bag-mask-ventilation (n=6, 19%)were themost common respiratory adverse
events.
Conclusions: Cerebral desaturation occurred in both patient groups, but there was no signiﬁcant difference between the two
groups. Based on primary outcome, both methods were shown to be comparable. Neurocognitive outcome was similar.
† This Article is accompanied by Editorial Aev402.
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The higher incidence of adverse events in the sedation group suggests a potential advantage of general anaesthesia.
Clinical trial registration: NCT 01251328.
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Editor’s key points
• Patients undergoing Transcatheter aortic valve implant-
ation (TAVI) can be managed using sedation techniques or
general anaesthesia.
• This small study compared moderate to deep sedation
using propofol and remifentanil with general anaesthesia.
• Therewere no differences in cerebral oxygenation or neuro-
cognitive outcome.
• The incidence of adverse events, principally pain and re-
spiratory depression, was much higher in the sedation
group.
• Moderate to deep sedation for TAVI has potential disadvan-
tages compared with general anaesthesia.
Since 2002 transfemoral transcatheter aortic valve implantation
(TAVI)1 has continuously evolved with different approaches
and techniques,2 for treatment of severe aortic valve stenosis. A
shift from general anaesthesia (TAVI-GA) towards sedation
(TAVI-S) has been increasingly described.3–6 Simpliﬁed monitor-
ing, shortened procedure time, less haemodynamic instability,
a decreased need for catecholamine therapy and shorter inten-
sive care unit (ICU) stays were presented as beneﬁts.7 8 It is note-
worthy that emergency conversion to general anaesthesia for
TAVI-S has been reported in up to 17% of patients.6 8
During procedural sedation, adverse events including hypox-
emia have been reported in up to 21% of patients.9 Cerebral oxy-
metry – as measured by Near-Infrared Spectroscopy (NIRS) – is a
way of monitoring perfusion and oxygenation.10 11 Induced car-
diac arrest for balloon valvuloplasty and hypotension during
valve release are two distinctive moments for cerebral desatur-
ation to occur during TAVI, comparablewith a decrease in cerebral
saturation observed during brief cardiac arrest for ICD-testing.12
In a different context perioperative cerebral desaturation has
been linked to increased postoperative major organ morbidity
and mortality.13 14 Postoperative cognitive decline has been
shown in desaturation of more than 3000 s%.15 Neither the de-
scribed beneﬁts for TAVI-S, nor the equivalent safety of both pro-
cedures were examined in a randomized trial.
In this study we hypothesized that the cumulative periopera-
tive cerebral desaturation is higher in patients undergoing TAVI-S
because of a presumed lower PaO2 and SaO2 and as a result from a
pilot study. As secondary endpoints we studied the difference in
neurocognitive function, arterial blood-gas-analysis (ABG) and
perioperative adverse events. In addition procedure-related
time periods were evaluated.
Methods
The INSERT (Near INfrared Spectroscopy in aortic valvE Replace-
menT) trial was a single-centre, controlled, parallel-group study
with balanced randomization (1:1). The trial was performed
from February 2011 to April 2012 at the Institut für Anästhesiolo-
gie, Deutsches Herzzentrum München, a university-hospital
specialized in cardiovascular diseases. Expert knowledge was
obtained from approximately 600 previous TAVI patients.
The study was approved by the medical ethics board of the
Technische Universität München (Clinical trials: NCT01251328).
Written informed consent was obtained from the patients
before enrolment.
Patients
Inclusion criteria: patients with acquired severe aortic stenosis
(age 18 yr and above), undergoing transfemoral CoreValve™
(Medtronic, Minneapolis, USA) implantation. The decision for
transcatheter treatment was made by the cardiac surgeons. Pa-
tients had to be eligible to undergo the procedure using general
anaesthesia or sedation and be able to undergo neurocognitive
testing. Comparable operative risk was determined from co-
morbidities and risk-scores (EUROscore, STS-Score).
Patients with a predicted difﬁcult airway,16 severe pulmonary
arterial hypertension (PAPsyst>60 mm Hg)
17 or CPAP-therapy for
obstructive sleep apnoea18 were excluded from the study. Add-
itional exclusion criteria were former/current alcohol or drug
abuse, neurocognitive/neurodegenerative disease or psychiatric
disorder, and use of antidepressants/sedatives.
Secondary exclusion criteriawere abortion of procedure, peri-
operative emergency conversion from sedation to general anaes-
thesia and the need for cardiopulmonary resuscitation during
the observation period, as the primary endpoint could not be
determined in these conditions.
A sealed envelope containing the treatment assignment was
allocated to the patients in the order of enrolment and opened at
the patient’s arrival in the operation room. The Institute of
Medical Statistics and Epidemiology, Technische Universität
München, provided the envelopes.
Treatment strategies
All patients received 3.75 mg of midazolam for oral premedica-
tion 30 min before arrival in the operating room. TAVI-GA and
TAVI-S were performed using weight-adapted doses of propofol
and remifentanil. TAVI-GA patients started with propofol 3 mg
kg−1 h−1 and remifentanil 0.2 mcg kg−1 min−1. A single dose of ro-
curonium (0.3mg kg−1) was administered for tracheal intubation.
In TAVI-S patients propofol 1 mg kg−1 h−1 and remifentanil 0.03
mcg kg−1 min−1 were used. In TAVI-S the cardiac surgeons inﬁl-
trated the groin with 10 ml of mepivacaine 1% at the beginning
of the procedure. To provide optimal implantation conditions
and to avoid patient movement especially during balloon valvu-
loplasty and valve implantation, moderate to deep sedation (ac-
cording to the ASA19 deﬁnition) was applied.
Depth of anaesthesia/sedation was monitored by Bispectral
Analysis (BIS™, Covidien, Dublin, Ireland) throughout the
whole course of anaesthesia and valve implantation. Values at
distinctive time-points are presented in Table 2. To achievemax-
imum oxygen supply, the inspiratory oxygen fraction (FO2) was
set to 1.0, and controlled ventilation was adjusted to an end-
expiratory CO2 of 4.6 kPa in TAVI-GA. TAVI-S patients received
8 Litre min−1 of oxygen for the same reason.
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Apart from standard perioperative monitoring in accordance
with ASA-guidelines, invasive arterial and central venous pres-
sure blood pressure monitoring were applied. Perioperative
transesophageal echocardiography was used in TAVI-GA pa-
tients, to monitor the result after implantation. Implantation
was guided byﬂuoroscopy in both groups. A temporary 5-Fr pace-
maker wire was inserted through the internal jugular vein for
rapid ventricular pacing (RVP). Intraoperative hypotension
(MAP<65 mm Hg)20 was treated with a single i.v. norepinephrine
bolus of ﬁve mcg. A continuous norepinephrine infusion was
started in case ﬁve or more bolus administrations were needed.
Haemodynamic parameters were documented at seven distinct
perioperative time-points (at baseline, after induction, during
and 60 s after RVP and valve implantation, and end of procedure).
During the implantation of the self-expanding CoreValve™, two
episodes of hypotension occured. The ﬁrst one was during
RVP-induced cardiac arrest for balloon valvuloplasty. The second
episode was as a result of the temporary obstruction of the left
ventricular outﬂow tract during valve implantation.
Two cardiac anaesthetistswith experience in both procedures
and perioperative care of TAVI patients (>250 patients each) were
assigned to these implantations. One anaesthetist was engaged
solely in study documentation, while the other anaesthetist con-
ducted patient care. Cardiac surgeons were responsible for post-
operative intensive care.
Primary endpoint
Procedure and anaesthesia-related impairment of circulation
and gas-exchange may affect cerebral oxygenation10 and initiate
cerebral desaturation as demonstrated by our pilot-patients (see
below). Therefore cerebral desaturation was chosen as a primary
endpoint, assuming that is was greater in TAVI-S patients.
Perioperative NIRS measurement was conducted in a blinded
‘study’mode. NIRSwasmonitored using INVOS 5100™ (Covidien,
Dublin, Ireland), which has been previously described in detail.11
Data were stored continuously in 6 s intervals, and analysed
using the INVOS Monitoring-System-Analytics-Tool© (Covidien,
Dublin, Ireland) after the last patient completed surgery. The
room air rSO2 baseline (rSO2-RA baseline) parameter was deﬁned
as the average rSO2 value in a 30 s period, during the insertion
of a radial artery catheter. Neither sedative drugs nor oxygen
Not meeting inclusion criteria (n=19)
refused to participate (n=5)
Excluded (n=24)
Randomized (n=66)
Allocated to Gen. Anaesthesia (n=33)
need for perioperative CPR (n=2)
Secondary exclusion
Analysed (n=31) Analysed (n=31)
Procedure aborted for surgical reasons (n=1)
need for CPR and emergency intubation (n=1)
Secondary exclusion
Allocated to Sedation (n=33)
Received Sedation (n=33)Received Gen. Anaesthesia (n=33)
Scheduled for procedure
(n=100)
Assessed for eligibility
(n=90)
Fig 1 CONSORT Flow Diagram.
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was administered before the measurement. An individual
desaturation threshold (rSO2-DESAT) was determined for each
patient. The threshold was deﬁned as a decrease of 20% below
the rSO2-RA baseline or an absolute value below 50%, whichever
was higher.15 In case of interhemispheric rSO2 differences
(rSO2-Δinterhem), the lower value hemisphere was used for
analysis.21 Area-under-the curve (AUC) analysis was conducted
to assess rSO2 decreases during the entire case.
15 The AUC was
calculated as
AUC rSO2-DESAT ¼ ½rSO2-DESATð%Þ  rSO2 currentð%Þ  time (Sec)
The primary endpoint (AUC rSO2 (total<DESAT)) was deﬁned as the
calculated summation of all AUC rSO2-DESAT.
Secondary endpoints
Neurocognitive outcome
All patients underwent neurocognitive testing the day before the
intervention and on the seventh postoperative day or the day of
hospital release (if earlier). The tests were provided by the Depart-
ment of Psychiatry, Technische Universität München, and con-
sisted of three parts. ‘DemTect’ is an age-adjusted screening test
for cognitive dysfunction. The DemTect scale ranges from 0 to 18
points, withmore than 13 points representing good age-based cog-
nitive function.22 ‘Zahlenverbindungstest’ (ZVT-1/2) examines the
perceptual speed needed to connect 30 apparently arbitrary num-
bers.23 ‘Regensburger-Wortﬂüssigkeitstest’ (RWT)24 is an educa-
tion-adjusted test to assess the formal lexical stream of speech.
Patients had to name as many words with a given ﬁrst letter (‘P’)
in a period of 2 min. Speech ﬂuency in the German language is
mandatory for these tests. At the time of the preoperative testing,
the randomized anaesthesia technique was unknown.
Arterial blood gas analysis (ABG)
ABG (PaO2 ; PaCO2 ; SaO2 ; haemoglobin, pH, and lactate) was per-
formed at baseline, after induction of anaesthesia, 60 s after
RVP, and 120 s after extubation.
Adverse events and procedure-related time periods
Anaesthesia and procedure-related adverse events were prede-
ﬁned and documented at the time of occurrence. ‘Difﬁcult air-
way’ was deﬁned according to ASA guidelines as a clinical
condition in which a trained anaesthetist experienced difﬁculty
with face-mask ventilation of the upper-airway, difﬁculty with
tracheal intubation, or both.16 ‘Difﬁcult central venous catheter’
was deﬁned as a clinical condition in which a trained anaesthe-
tist neededmore than 2 attempts of puncturing the internal jugu-
lar vein, despite the use of ultrasound, difﬁculty in advancing the
guidewire, or both. ‘Deﬁbrillation’was used in a clinical condition
with tachyarrhythmia and hypotension. ‘Jaw-thrust-manoeuvre’
was used in case of upper airway obstruction because of loss of
pharyngealmuscle tone. A ‘nasopharyngeal airway’was inserted
in situations of a permanent need of jaw-thrust-manoeuvre.
‘Bag-valve mask ventilation’ was used in patients with bradyp-
noea/apnoea and/or hypoxia. ‘Bradypnoea’ was deﬁned as a re-
spiratory rate <8 min−1. ‘Hypoxia’ was deﬁned as a SpO2 < 90%
over 10 s.9 ‘Unrest/pain’ was deﬁned as any undesired targeted/
untargeted movement from the patient or expression of pain
throughout the whole anaesthetic and interventional procedure.
Statistical analysis
Categorical data are presented as absolute and relative frequen-
cies. Group comparisonswere performed using χ2tests or Fisher’s
exact test depending on the expected cell counts of correspond-
ing contingency tables. The distribution of continuous data is
given by the median and interquartile range (IQR=25–75th per-
centile). Mann-WhitneyU-tests andHodges-Lehmann 95% conﬁ-
dence intervals were used to assess differences between groups.
All statistical tests were performed using a two-sided 5% signiﬁ-
cance level. Derived from a pilot study, expected mean AUC
rSO2 (total<DESAT) of 2000 s% (TAVI-S) and 1000 s% (TAVI-GA) with
standard deviations of 1500 and 500 have been used for a conser-
vative sample size calculation. A group size of 28 individuals
was found to result in a 90% power (β=10%) for a two-sided two-
sample t-test to detect such a difference of α=5% level of signiﬁ-
cance (N-Query Advisor 7.0). The application of Pitmans ARE
(Asymptotic Relative Efﬁciency)=0.864 lead to an adjusted sample
size of 28/0.864=32.4 which is approximately 33 subjects per
treatment arm. SPSS Vers.21 (IBM, Germany) and SAS Enterprise
Guide 4.3 (SAS Institute, Cary, USA) were used for analysis.
Results
In the study period 100 patients were undergoing transfemoral
CoreValve™ implantation, 66 patients (33 TAVI-GA, 33 TAVI-S)
were enrolled. Details of patient enrolment are shown in Fig. 1.
Two TAVI-GA patients were excluded because of the need for
perioperative cardio-pulmonary resuscitation (CPR). Both pa-
tients required CPR after valve implantation. The ﬁrst one as a
result of prolonged hypotension. At the end of the procedure
the patient needed a second episode of resuscitation and drain-
age of pericardial effusion. After four days of ICU care the patient
was discharged on POD 8. The other patient was resuscitated as a
result of prolonged ventricular ﬁbrillation. At the end of oper-
ation the patient was transferred awake to the ICU for a three-
day stay and discharged on POD 9. One TAVI-S patient was ex-
cluded because of CPR and emergency conversion to general an-
aesthesia, as a result of signs of heart failure and respiratory
distress at the beginning of sedation. After recompensation
Table 1 Preoperative patient characteristics. Data are given as
median and 25–75th percentile for continuous variables.
Categorical variables are given as percentage. BMI, Body Mass
Index; NYHA, New York Heart Association classiﬁcation; ASA,
American Society of Anesthesiologists classiﬁcation; STS,
Society of Thoracic Surgeons
TAVI-GA TAVI-S
n=31 n=31
Female patients n ( %) 18 (58) 13 (42)
Age (yr) 80 (75/84) 84 (79/86)
BMI (kg/m2) 25 (23/30) 27 (24/29)
Aortic Valve Area (cm2) 0.70 (0.56/0.83) 0.63 (0.60/0.80)
Left-Ventricular Ejection
Fraction (%)
55 (43/60) 57 (40/62)
Pulmonary Artery
Pressure (mm Hg)
43 (35/50) 47 (42/60)
Mean pressure gradient
aortic valve (mm Hg)
54 (37/69) 46 (40/56)
Maximum pressure
gradient aortic valve
(mm Hg)
64 (45/88) 65 (45/82)
NYHA (III/IV) n (%) 24 (77) 22 (71)
EUROScore log (%)* 9.72 (7.01/18.26) 11.66 (10.32/21.43)
STS Mortality Score (%) 4.3 (2.8/10.2) 5.0 (3.6/7.4)
STS Morbidity Score (%) 23.3 (16.9/32.4) 25.4 (19.6/29.7)
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transfemoral CoreValve™ was successfully implanted. The pa-
tient was extubated at the end of procedure and discharged
home POD 13.
One additional TAVI-S patient was excluded because of difﬁ-
culties with femoral vascular access and abortion of the proced-
ure. In each group, 31 allocated patients were analysed.
Table 2 Perioperative course of rSO2 and procedure related values. Data are given asmedian and 25–75th percentile for continuous variables.
Categorical variables are given as percentage. rSO2, Cerebral Saturation; ICU, IntensiveCareUnit; BIS, Bispectral index; RVP, Rapid ventricular
pacing. *Indicates a P<0.05
TAVI-GA TAVI-S P-value
n=31 n=31
Procedure related timeline
Induction time (min) 45 (40/50) 43 (35/50) 0.276
Duration of procedure (min) 72 (62/85) 75 (62/90) 0.667
Skin closure to extubation or equivalent alertness (min) 1 (−2/4) −1 (−4/3) 0.235
Arrival of patient to handover to ICU (min) 170 (155/185) 170 (153/185) 0.983
Duration RVP (s) 22 (17/28) 21 (18/25) 0.621
Duration Valve implantation (s) 230 (170/339) 300 (179/376) 0.371
rSO2 values
rSO2 at room air baseline (%) 60 (53/66) 57 (54/67) 0.916
rSO2 interhemispheric difference (%) 0 (−3/3) 0 (−5/3) 0.789
rSO2 with oxygen after induction (%) 65 (58/70) 68 (63/78) 0.111
rSO2 before RVP (%) 68 (60/71) 70 (64/79) 0.107
rSO2 minimal value during RVP (%) 58 (51/64) 60 (56/67) 0.323
rSO2 before valve implantation (%) 68 (58/72) 69 (64/78) 0.161
rSO2 minimal value during valve impl. (%) 60 (51/66) 62 (54/71) 0.430
rSO2 120 S after extubation (%) 73 (62/78) 72 (66/76) 0.921
Drug usage
Remifentanil total (µg/kg) 25.3 (18.3/34.7) 4.5 (3.7/5.2) <0.001*
Propofol total (mg/kg) 8.3 (6.1/9.9) 2.6 (2.1/3.6) <0.001*
Norepinephrine total (µg/kg) 1.95 (1.07/4.78) 1.67 (0.62/3.13) 0.495
Depth of Anaesthesia
BIS pre-induction 97 (92/98) 95 (89/97) 0.155
BIS at entering OR 40 (37/46) 83 (73/86) <0.001
BIS before RVP 40 (36/43) 72 (58/81) <0.001
BIS during RVP (minimal value) 39 (34/40) 60 (51/74) <0.001
BIS during valve release (minimal value) 39 (31/46) 56 (50/75) <0.001
BIS during skin closure 86 (75/95) 89 (86/92) 0.486
Postoperative
Stay on ICU (days) 2 (1/4) 4 (1/6) 0.019*
Stay on Ward (days) 4 (3/6) 5 (2/6) 0.603
Total stay in hospital (days) 7 (6/8) 8 (7/11) 0.050
In hospital mortality n (%) 0 1 (3) 1.000
Adverse events
Unrest/Pain n (%) 0 19 (61) <0.001*
Bradypnoea n (%) n.a. 16 (52) n.a.
SpO2<90% n (%) 0 5 (16) 0.053
Jaw-Thrust/nasopharyngeal airway n (%) n.a. 11 (36) n.a.
Bag-Mask Ventilation n (%) n.a. 6 (19) n.a.
Difﬁcult tracheal intubation n (%) 3 (10) n.a. n.a.
Bronchospasm n (%) 0 1 (3) 1.000
Difﬁcult central venous catheter n (%) 1 (3) 3 (10) 0.612
Deﬁbrillation n (%) 0 1 (3) 1.000
Perioperative Stroke n (%) 0 1 (3) 1.000
Cumulative no. of patients with adverse events n (%) 4 (13) 29 (94) <0.001*
Renal parameters
Creatinine at time of admission (mg/dl) 0.91 (0.78/1.03) 0.94 (0.74/1.34) 0.205
Creatinine at time of discharge (mg/dl) 0.92 (0.81/1.10) 0.86 (0.67/1.32) 0.899
Need for dialysis n (%) 0 2 (6) 0.492
Procedural outcome n=29 n=27
Mean pressure gradient aortic valve at time of discharge (mm Hg) 11 (7/12) 12 (9/15) 0.079
Aortic Valve Area at time of discharge (cm2) 1.55 (1.29/1.79) 1.50 (1.35/1.80) 0.975
Aortic Regurgitation at discharge n=29 n=29 0.315
Grade 0 (%) 13 (45) 7 (26)
Grade I (%) 14 (48) 16 (59)
Grade II (%) 2 (7) 4 (15)
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As shown in Table 1, the patients’ preoperative baseline char-
acteristics were comparable. Median age of TAVI-S patients was
4 yr higher leading to a higher logistic EUROscore, while other
risk scores (STS) were comparable.
Primary endpoint
There was no signiﬁcant difference in AUC rSO2 (total<DESAT)
(Fig. 2C) between TAVI-GA (median [IQR]) (0 [0/1308] s%) and
TAVI-S (0 [0/276] s%, P=0.505).
Sensitivity analysis
There was no difference in rSO2 values between the two groups
(Table 2). All patients showed a decrease in rSO2 during RVP and
valve implantation (Fig. 2A and B). The baseline values of rSO2
before these interventions were comparable (Table 2). Twenty-
four patients (39%) experienced perioperative decrease in rSO2
below the desaturation threshold (TAVI-GA: n=13, TAVI-S: n=11;
P=0.602). Maximal calculated desaturation was 27 174 s% in
TAVI-GA and 14 502 s% in TAVI-S patients. Eight of these
patients (TAVI-GA: n=5, TAVI-S: n=3; P=0.707) experienced a
cumulative perioperative desaturation of more than 3000 s%
(Fig. 2C).
Secondary endpoints
Neurocognitive outcome
All three neurocognitive tests revealed no signiﬁcant pre- to post-
operative difference neither within nor between the two patient
groups (Fig. 3). Memory function (DemTect) was comparable be-
tween TAVI-GA (0 [−2/2] points) and TAVI-S (0 [−2/2] points,
P=0.817). Both parts of the ZVT (ZVT 1: TAVI-GA: 3 [−4/14] s,
TAVI-S: −2 [−7/8] s, P=0.307; ZVT 2: TAVI-GA: 2 [−5/8] s, TAVI-S: 3
[−4/18] s, P=0.362) revealed no difference in pre- to postoperative
testing. Executive function (RWT) was also similar in both groups
(TAVI-GA: −1 [−3/3] s, TAVI-S: 0 [−3/2] words, P=0.815).
Arterial blood gas analysis
As shown in Fig. 4, baseline ABG measurements were similar in
both groups. In the TAVI-S group PaCO2 increased signiﬁcantly
after the start of sedation (TAVI-GA: (5.2 [4.6/5.5] kPa; TAVI-S: 6.7
[6.0/7.5] kPa, P<0.001) and continued to stay higher periopera-
tively. Simultaneously, respiratory acidosis was observed (pH
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TAVI-GA: (7.45 [7.41/7.48]; pH TAVI-S: 7.35 [7.31/7.42], P<0.001).
PaO2 was signiﬁcantly higher in TAVI-GA patients during this per-
iod (TAVI-GA: (48 [39.3/53.3] kPa; TAVI-S: 22.8 [16.3/27.2] kPa,
P<0.001). At the end of the procedure, ABG values were similar
in both groups. Haemoglobin values remained comparable dur-
ing the procedure (Fig. 4).
Adverse events and procedure-related time periods
Several perioperative adverse events occurred during the study,
as shown in Table 2. In 29 of 31 (94%) TAVI-S and in 4 of 31
TAVI-GA patients (13%) (P<0.001) adverse events were observed.
One TAVI-S suffered a perioperative severe stroke (conﬁrmed by
neuroimaging) without signs of cerebral desaturation. This pa-
tient was transferred to an external ICU and died on POD 19. A se-
cond TAVI-S patient was re-admitted to ICU on POD 8 and died on
POD 22 from septic multi-organ failure.
Induction time, procedure time, and time from arrival of the
patient until handover to the ICU were comparable as shown in
Table 2. The anaesthetic drug dosage was higher in TAVI-GA pa-
tients. As to be expected, perioperative BIS values were lower in
TAVI-GA (Table 2) during the operation. Therewas no statistically
signiﬁcant difference in catecholamine use. The ICU stay was
statistically signiﬁcantly shorter in TAVI-GA patients (TAVI-GA:
2 [1/4] days; TAVI-S: 4 [1/6] days; P=0.019)).
Procedural outcome and postoperative kidney injury
Procedural outcome deﬁned as aortic regurgitation, mean pres-
sure gradient and aortic valve area at dischargewere comparable
in TAVI-GA and TAVI-S patients (Table 2). Two TAVI-S patients re-
quired temporary postoperative dialysis. Pre- and postoperative
creatinine values did not differ between TAVI-GA and TAVI-S
patients (Table 2).
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Discussion
The results of this study show that cerebral desaturation oc-
curred both during general anaesthesia and sedation without a
statistically signiﬁcant and clinical difference in primary out-
come (Table 2, Fig. 2). Sedationwas associatedwithmore adverse
events, such as respiratory events. Longer periods of cerebral de-
saturations are associated with adverse outcome. In this study
episodes of perioperative cerebral desaturation were monitored
especially during balloon valvuloplasty and valve implantation,
but were too short to produce desaturation to a larger extend.
Our data are comparable with those recently published in a co-
hort of patients undergoing cardiac surgery21 and baseline values
described in patients undergoing transapical TAVI.25 Although
NIRS is a localized trend monitoring and only parts of the frontal
lobe are monitored for signs of hypoperfusion and/or desatur-
ation, it is the best available method to monitor the common
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endpoint of cerebral perfusion and oxygenation. In addition
the chosen desaturation threshold complies with the current
consensus.15 Although extracranial contamination has been de-
scribed, with INVOS™we used the technique that has been used
in most trials.14 15 21
Three neurocognitive tests examining different types of cog-
nitive function did not reveal any signiﬁcant difference between
pre- and postoperative testing. These data are in accordancewith
results recently published,26 showing that more than 90% of se-
dated TAVI patients had no signs of cognitive deﬁcit. From our
point of view, neither general anaesthesia nor sedation impairs
postoperative neurocognitive function in this speciﬁc group of
patients (Fig. 3).
Perioperative PaCO2 was signiﬁcantly higher in TAVI-S pa-
tients with consecutive respiratory acidosis. In moderate to
deep sedation PaCO2 is often difﬁcult to control as most seda-
tives and opioids affect respiration to a certain degree.25
Respiratory depression, hypercarbia, and acidosis may increase
pulmonary artery pressure (PAP) andmay lead to right ventricu-
lar failure.27 Pulmonary hypertension (PH) has been described
in TAVI patients in up to 50%.28 As PAP is easier to control, we
consider general anaesthesia as favourable in patients with
pre-existing PH.
Shorter procedure times for TAVI-S have been described7 29
but these studies were not randomized. In addition different
ways of haemodynamic monitoring, different techniques for
femoral access and different periods of the learning curve were
compared. Our study was performed with an experienced team,
and the same haemodynamic monitoring was used, showing no
time-beneﬁt for sedation. On the contrary, ICU stay was signiﬁ-
cantly shorter in TAVI-GA patients. The reason for this difference
remains unclear.
Several adverse eventswere observed in our study. A high rate
of respiratory events and the need for bag-valvemask ventilation
in 19% of TAVI-S patients, occurred even in the presence of ex-
perienced anaesthetists (Table 2). This number is in agreement
with a previously described rate of unplanned perioperative intu-
bations of 17%.6 Unrest and pain may not be considered severe
adverse events but are disturbing for the surgeon. Movement of
the legs may also cause injury to the femoral vessels. Despite
moderate to deep sedation and inﬁltration of local anaesthesia,
unrest and pain were common during sedation. These adverse
events in TAVI-S patients expose the potential risks of moderate
to deep sedation for this procedure. There was no signiﬁcant im-
pact of anaesthesia to the implantation result. The tendency to-
wards more aortic regurgitation in TAVI-S is in accordance with
the recent published FRANCE-2 registry.30 With the introduction
of novel devices and the reduction of the diameter of the delivery
system to 14 French, unrest and pain may be less problematic.
As the experience with these new devices is rapidly growing,
moderate or even minimal sedation might be sufﬁcient and
decrease the rate of respiratory events.16 Further studies are
needed to prove this concept.
Limitations
This study was powered for the primary endpoint of cerebral de-
saturation and not for the secondary outcome parameters of
neurocognitive outcome and adverse events. This might be a
limitation for these results. As we did notmeasure PAP, the effect
of hypercapnia on the right ventricular function and PAP in our
TAVI-S patients remains unclear. Although the studywas blinded
for most parts, the anaesthesia technique could not be blinded
for obvious reasons.
Conclusion
In summary, TAVI in sedation did not offer an advantagewith re-
spect to cerebral desaturation and neurocognitive outcome com-
pared with general anaesthesia. Moreover sedation was
associated with more adverse events, such as respiratory events,
and ICU longer stays. Therefore these data suggest an advantage
of general anaesthesia vsmoderate to deep sedation.
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